• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Prolonged impairment of deglutition in supratentorial ischaemic stroke: the predictive value of Parramatta Hospitals' Assessment of Dysphagia.
CONCLUSIONS: In a selected population at risk of aspiration, the PHAD with a threshold of 70 assessed in the second week after stroke onset may be a valuable tool to predict prolonged impairment of deglutition for another 4 weeks and to guide the decision about switching from NG to PEG tube feeding after supratentorial ischaemic stroke. PMID: 27684427 [PubMed - as supplied by publisher]
Source: Swiss Medical Weekly - October 1, 2016 Category: Journals (General) Authors: Kägi G, Leisi N, Galovic M, Müller-Baumberger M, Krammer W, Weder B Tags: Swiss Med Wkly Source Type: research

Association of Long-Term Exposure to Transportation Noise and Traffic-Related Air Pollution with the Incidence of Diabetes: A Prospective Cohort Study
Conclusion: We found a positive association between residential transportation noise and diabetes, adding to the growing body of evidence that noise pollution exposure may be independently linked to metabolic health and should be considered when developing public health interventions. https://doi.org/10.1289/EHP1279 Received: 26 October 2016 Revised: 07 May 2017 Accepted: 09 May 2017 Published: 31 August 2017 Address correspondence to C. Clark, Ove Arup and Partners, Acoustics, 13 Fitzroy Street, London, W1T 4BQ, UK. Telephone: +44 207755 4702. Email: Charlotte.Clark@arup.com The authors declare they have no actual o...
Source: EHP Research - August 31, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Roche ’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
Fenebrutinib is an investigational, potent and highly selective oralBruton ’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase II study met its primary and secondary endpoints by reducing the total number of new gadolinium-enhancing T1 brain lesions and significantly reducing the total number of new or enlarging T2 brain lesions compared to placeboThe safety profile offenebrutinib was consistent with previous and ongoing clinical trials across more than 2,400 people to dateBasel, 17 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today p...
Source: Roche Media News - May 17, 2023 Category: Pharmaceuticals Source Type: news

Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news